Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Revive Therapeutics Ltd
C.RVV
Alternate Symbol(s):
RVVTF
Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is...
evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:RVV)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 09, 2023 3:35pm
New Press Release - Revive Therapeutics Announces Publication Showing Bucillamine's Potential Impact on COVID-19 Omicron Variants
TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces an independent...
read article.
(7)
•••
90guppy
X
View Profile
View Bullboard History
Comment by
90guppy
on Jan 09, 2023 9:24am
RE:China - to include Paxlovid in state health insurance fail !
FO-OL, aka Cool, all you have to do is call out the mgt to make sure they dont blow the type c WRO. That is all rvv needs to do, be on top of the type c WRO requirement and dont mess up. This China
...more
(5)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 08, 2023 6:39am
China - to include Paxlovid in state health insurance fail !
#bucillamine https://news.yahoo.com/china-says-talks-paxlovid-state-103912764.html
(5)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 06, 2023 1:50pm
China in talks with Pfizer for generic COVID drug - sources
#Bucillamine https://www.devdiscourse.com/article/health/2311027-exclusive-china-in-talks-with-pfizer-for-generic-covid-drug---sources?amp
(5)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 05, 2023 5:13pm
$RVV - fyi ..
#Bucillamine
(5)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 05, 2023 9:31am
$RVV Update !
https://ca.finance.yahoo.com/news/revive-therapeutics-announces-type-c-141900186.html
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 05, 2023 9:19am
New Press Release - Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
TORONTO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the U.S....
read article.
(7)
•••
90guppy
X
View Profile
View Bullboard History
Comment by
90guppy
on Jan 03, 2023 9:27am
RE:CDC tracking rise of new XBB.1.5 COVID variant !
Cool, u r a Fo-ol, like the mgt for dropping the ball
(876)
•••
CrazyProphet
X
View Profile
View Bullboard History
Post by
CrazyProphet
on Jan 03, 2023 8:48am
Time to Rock n Roll
(5)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Dec 31, 2022 9:57pm
Happy New Year Revive Family ! Best Wishes to ALL !!
(5)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Dec 31, 2022 10:19am
CDC tracking rise of new XBB.1.5 COVID variant !
#Bucillamine https://www.cbsnews.com/news/covid-variant-xbb-1-5-cdc-tracking-us-cases/?ftag=CNM-00-10aab8d&linkId=195514720
(876)
•••
CrazyProphet
X
View Profile
View Bullboard History
Post by
CrazyProphet
on Dec 31, 2022 9:42am
Nothing but up 😽👀⬆️
https://twitter.com/StoicAdvisory/status/1608963533454336000?s=20&t=RyleuehFbtgQ32aL8haYIg https://twitter.com/CharlieMunger00/status/1608965674109636608?s=20&t=RyleuehFbtgQ32aL8haYIg
(5)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Dec 30, 2022 7:29pm
FDA broke own protocols in approving Biogen Alzheimer’s drug
https://www.nbcnews.com/health/health-news/fda-broke-protocols-approving-biogen-alzheimers-drug-congressional-rep-rcna63662
(5)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Dec 30, 2022 6:23am
China Approves Merck’s Covid Antiviral Amid Shortage of Drug
#Bucillamine https://www.bnnbloomberg.ca/china-approves-merck-s-covid-antiviral-amid-shortage-of-drugs-1.1864364
(12)
•••
DehydraTECH
X
View Profile
View Bullboard History
Post by
DehydraTECH
on Dec 23, 2022 5:18pm
Only 25 million cap EDSA
FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate 2022-12-20 08:31 ET - News Release Fast Track improves the speed and frequency of communication with
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >